Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Evaxion Biotech ( (EVAX) ) has shared an announcement.
On January 31, 2025, Evaxion Biotech A/S announced the successful closing of a $10.8 million public offering of American Depositary Shares (ADSs) and warrants. The funds are intended to advance the company’s clinical and preclinical pipeline, supporting ongoing operations and research. Notably, MSD Global Health Innovation Fund, a corporate venture capital arm of Merck & Co., Inc., participated in the offering, highlighting confidence in Evaxion’s innovative approach in the biotech industry.
More about Evaxion Biotech
Evaxion Biotech A/S is a pioneering TechBio company specializing in AI-Immunology™ powered vaccines. Their AI platform is used to develop novel immunotherapies for cancer, bacterial diseases, and viral infections. The company is based in Denmark and has developed a clinical-stage oncology pipeline and a preclinical infectious disease pipeline addressing high unmet medical needs.
YTD Price Performance: -41.61%
Average Trading Volume: 1,189,950
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.9M
See more data about EVAX stock on TipRanks’ Stock Analysis page.
